Plasma Donation Statistics in Canada 2026 | Donors, Clinics & Key Facts

What is Plasma Donation?

Plasma donation is the process of giving the straw-colored liquid portion of blood — which makes up roughly 55% of total blood volume — so it can be transfused directly into patients or manufactured into life-saving medications like immunoglobulin, albumin, and clotting factors. In Canada, plasma is collected through two parallel systems: the 100% voluntary, unpaid system run by Canadian Blood Services (CBS) and Héma-Québec, which supplies blood and plasma for direct transfusion, and a smaller paid, for-profit system operated exclusively by the Spanish pharmaceutical company Grifols, which pays donors to collect “source plasma” used to manufacture immunoglobulin medications domestically for the first time in Canadian history.

As of August 2026, Canada’s plasma donation system is in the middle of its most turbulent period in over a decade. Just yesterday, Grifols voluntarily paused all plasma collection at every one of its Canadian clinics, following a Health Canada non-compliance finding and mounting public scrutiny over donor deaths and adverse reactions. This report compiles the most current, verified plasma donation statistics in Canada for 2026 — covering the Grifols shutdown, donor safety data, self-sufficiency progress, Canadian Blood Services’ own plasma network, and the country’s ongoing dependency on the United States for the majority of its immunoglobulin supply.

Interesting Facts About Plasma Donation in Canada 2026

Source: CBC News; Global News; Health Canada; Canadian Blood Services; Ontario Health Coalition

These figures capture a system caught between two competing realities in 2026: Canada has made genuine progress toward plasma self-sufficiency, more than doubling its domestic immunoglobulin supply from 15% to 31% in just three years, yet that progress has come almost entirely through a for-profit, paid-donor model that yesterday’s shutdown shows may be fundamentally unstable. With 25 serious adverse reactions and 3 confirmed deaths tied to Grifols-run clinics, and over 90% of all serious reaction reports nationally originating from paid sites despite them collecting a minority share of Canada’s plasma, the events of August 13, 2026 mark a turning point that the rest of this report examines in detail.

Grifols Plasma Collection Pause Statistics in Canada 2026

Source: Global News; CBC News; Health Canada

The August 13, 2026 pause did not happen in isolation — it landed on the same day Health Canada released the results of an investigation finding multiple compliance concerns, including a formal non-compliance rating for the Winnipeg clinic where a fatal adverse reaction was reported in January 2026. Grifols has framed the closure as voluntary and tied to “unfounded attention,” but the timing, alongside six non-compliance notices issued across five provinces since 2022, suggests a company under sustained regulatory pressure rather than one acting purely out of caution. Health Canada has been explicit that the pause will not affect the safety or security of Canada’s blood supply, since Grifols’ paid-donor collections feed the immunoglobulin manufacturing pipeline rather than direct transfusion stocks — but the episode leaves Canada’s fragile plasma self-sufficiency progress stalled indefinitely while every one of the company’s Canadian sites remains offline.

Canada Plasma Donor Deaths & Adverse Reaction Statistics 2026

Source: CBC News; The Globe and Mail; Canadian Centre for Policy Alternatives

The statistic that more than 90% of all serious adverse reactions reported in Canada between 2016 and 2026 came from establishments now owned by Grifols is the single most consequential data point in this entire dataset, because paid, for-profit clinics represent only a fraction of the plasma collected nationally. Researcher Andrew Longhurst of the Canadian Centre for Policy Alternatives has called the concentration “deeply concerning” and is pushing for an independent review of Canada’s plasma system to explain why paid centres report so disproportionately many severe reactions to what medical experts consider an otherwise very safe procedure. The case of 22-year-old Rodiyat Alabede, an international student who died after donating plasma in Winnipeg, became a flashpoint after documents revealed the collection machine issued five separate alerts during her donation — one requiring intervention — that were not disclosed in Grifols’ initial report to Health Canada, a finding that directly undermines the company’s public assurances that donor safety “has never been compromised.”

Grifols Clinic Network & Regulatory Compliance Statistics in Canada 2026

Source: CBC News; Ontario Health Coalition; Canadian Blood Services

Grifols built out a 17-clinic network across five provinces in under four years under its 15-year agreement with Canadian Blood Services, signed in September 2022 specifically to close Canada’s immunoglobulin supply gap. That expansion came with an approval to collect plasma at roughly double the rate of CBS’s own voluntary centres — a business model advantage that helped Grifols scale quickly but also, critics argue, created pressure that compromised donor screening. A Health Canada inspection report found the company had repeatedly cleared donors at risk for Creutzfeldt-Jakob disease after changing its exclusion criteria in March 2025, and separately found Winnipeg centres operating dangerously over capacity. CBC’s review of the inspection database also found Grifols-run Winnipeg centres frequently went more than a year without a recorded blood-safety inspection, a gap regulators are now under pressure to close before any of the paused clinics are permitted to reopen.

Canada Plasma Self-Sufficiency Statistics 2026

Source: Ontario Health Coalition; Canadian Blood Services; Federal Retirees; The World Data

The jump in domestic immunoglobulin self-sufficiency from roughly 13–15% in 2022 to 31% by September 2025 represents real, measurable progress toward Canada’s stated 50% self-sufficiency target, split between a 25% contribution from CBS’s own voluntary centres and a matching 25% from Grifols’ paid-donor network. But that structure means the Grifols pause announced yesterday directly threatens half of Canada’s self-sufficiency strategy, since there is currently no equivalent voluntary-donor pathway that can replace paid collection at the same volume in the short term. Canada’s historical reliance on the United States — importing plasma equivalent to the output of 38 US collection centres in 2023 alone, according to Cornell Emerging Markets Institute data cited in the Blood Plasma Statistics in US report — underscores exactly why Ottawa pursued the paid-plasma expansion in the first place, even as this week’s events raise fresh questions about whether that path is sustainable without stronger oversight.

Canadian Blood Services & Héma-Québec Plasma Donor Statistics 2026

Source: Canadian Blood Services; Federal Retirees; Héma-Québec

Canadian Blood Services’ own 8 dedicated plasma donor centres, all unpaid and voluntary, form the backbone of the 25% CBS contribution toward national self-sufficiency, but they are contending with a broader donation crisis this summer: CBS reported on July 22, 2026 that overall blood supply had fallen nearly 20% since June 1, with weekly booked appointments running 1,500 to 2,500 short of the roughly 18,000 needed to keep pace with hospital demand. Quebec, which operates independently through Héma-Québec, faces the same structural challenge with a donation rate of just 3% of the population — even lower than the already-low 4% national average — despite a patient needing a blood transfusion every 80 seconds in the province, according to Héma-Québec’s own public relations director. Quebec’s plasma self-sufficiency of 35%, with a target of 42% by 2027, currently depends on shipping collected plasma to Europe for fractionation, illustrating that even Canada’s most self-sufficient province remains dependent on international infrastructure to turn donated plasma into usable medication.

For broader context on the strain facing Canada’s healthcare system this year, see our Hospital Emergency Room Statistics in Canada report, and for the cardiovascular conditions that plasma-derived therapies often support, our Canada Heart Disease Statistics report offers additional detail.

Canada vs. US Plasma Industry Comparison Statistics 2026

Source: Canada.ca; Health Canada; FDA

Canada’s plasma system operates on a fundamentally smaller scale and a more restrictive philosophy than its southern neighbor: the country maintains a 100% voluntary, non-remunerated commitment for transfusable blood and plasma, permitting paid donation only through Grifols and solely for pharmaceutical manufacturing purposes — a policy line that explains why Canada’s 25-clinic combined network looks minuscule next to the 1,247 centres operating across the United States. That scale gap is precisely why Canada remains structurally dependent on American supply: the US alone provides 70% of the world’s plasma, and Canadian patients have relied on that dominance for the majority of their immunoglobulin needs for over a decade. With Grifols’ 17 Canadian clinics now paused indefinitely following this week’s regulatory action, Canada’s already-modest domestic collection capacity has, for the moment, shrunk back down to just the 8 CBS-run centres — a reminder of how thin the margin for self-sufficiency remains even after several years of deliberate policy investment.

Plasma Donor Eligibility & Public Reaction Statistics in Canada 2026

Source: Global News; CBC News; BloodWatch.org

Public reaction to the Grifols pause has split sharply along the same lines that have defined the paid-plasma debate in Canada since the model was first introduced. Donors themselves, commenting directly on the news, described losing a reliable source of supplemental income they used for rent, debt repayment, and emergency expenses — echoing the same economic dependency documented among American donors. Advocacy groups like BloodWatch.org, however, have used the shutdown to renew calls for Canadian Blood Services leadership accountability and, ultimately, the cancellation of the Grifols agreement entirely, arguing the for-profit paid-plasma model should never have been introduced into what Canada has otherwise maintained as a voluntary blood system since the 1997 Krever Inquiry into the tainted-blood scandal. That inquiry’s legacy — the federal blood safety contribution program, which is scheduled to end on March 31, 2026 — adds another layer of uncertainty to how Canada funds and oversees plasma safety just as its highest-volume paid collector sits offline indefinitely.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE